180 Life Sciences Corp. (ATNF): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATNF Stock Price Chart Interactive Chart >
ATNF Price/Volume Stats
| Current price | $3.33 | 52-week high | $71.40 |
| Prev. close | $3.30 | 52-week low | $1.18 |
| Day low | $3.25 | Volume | 193,767 |
| Day high | $3.40 | Avg. volume | 6,579,993 |
| 50-day MA | $5.08 | Dividend yield | N/A |
| 200-day MA | $16.37 | Market Cap | 6.74M |
180 Life Sciences Corp. (ATNF) Company Bio
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.
Latest ATNF News From Around the Web
Below are the latest news stories about 180 LIFE SCIENCES CORP that investors may wish to consider to help them evaluate ATNF as an investment opportunity.
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s DiseasePALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery (European Volume). In the publication, Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, and his colleague at the University of Oxford, describe the limitations for th |
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United KingdomPALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application (MAA) for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA or Agency). As part of the ap |
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price RequirementPALO ALTO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As indicated in the letter, Nasdaq determined that for 1 |
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s DiseasePALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren’s disease: a localized and accessible human fibrotic disorder’ in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe the biology of Dupuytren’s diseas |
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to ShareholdersPALO ALTO, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Dear Fellow Shareholder, As we come to the end of 2022, I am pleased to provide an update for our shareholders. In keeping with good corporate practice and US Securities and Exchange Commission (SEC) regulations, we have refrained from answering individual queries from shareholders until we were able to provide information to all shareholders at the same time. Our priorities continue to be our clinical programs, repurposing anti-Tumor Necrosis |
ATNF Price Returns
| 1-mo | -1.77% |
| 3-mo | -60.43% |
| 6-mo | -86.99% |
| 1-year | -94.18% |
| 3-year | -98.45% |
| 5-year | N/A |
| YTD | -1.77% |
| 2022 | -95.65% |
| 2021 | 42.86% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...